[{"id":"86dcbaa4-a0f7-4722-b301-afe751349fdb","acronym":"","url":"https://clinicaltrials.gov/study/NCT07479485","created_at":"2026-03-28T01:39:14.150Z","updated_at":"2026-03-28T01:39:14.150Z","phase":"Phase 1/2","brief_title":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","source_id_and_acronym":"NCT07479485","lead_sponsor":"Lepu Biopharma Co., Ltd.","biomarkers":" GPC3","pipe":"","alterations":" ","tags":["GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Puyouheng (pucotenlimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 04/01/2026","start_date":" 04/01/2026","primary_txt":" Primary completion: 04/01/2028","primary_completion_date":" 04/01/2028","study_txt":" Completion: 04/01/2029","study_completion_date":" 04/01/2029","last_update_posted":"2026-03-18"},{"id":"77fa5f49-487a-4db1-b519-6ab7e22a9571","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616443","created_at":"2021-01-19T20:33:37.345Z","updated_at":"2024-07-02T16:35:56.720Z","phase":"Phase 1/2","brief_title":"OH2 Injection in Combination With HX008 for Melanoma.","source_id_and_acronym":"NCT04616443","lead_sponsor":"Binhui Biopharmaceutical Co., Ltd.","biomarkers":" CD8 • CD4","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8 • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab) • BS001"],"overall_status":"Recruiting","enrollment":" Enrollment 60","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 11/30/2023","primary_completion_date":" 11/30/2023","study_txt":" Completion: 11/30/2023","study_completion_date":" 11/30/2023","last_update_posted":"2023-01-31"},{"id":"c02436a4-c327-4010-b280-df7280202ef3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05688605","created_at":"2023-01-18T14:59:52.605Z","updated_at":"2024-07-02T16:35:57.487Z","phase":"Phase 1/2","brief_title":"A Study of MRG003 in the Treatment of Patients With EGFR-positive Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT05688605","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab) • Meiyouheng (becotatug vedotin)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 06/30/2022","start_date":" 06/30/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2023-01-18"},{"id":"a3e5bdf7-ffe4-482f-9a02-43f71819cb03","acronym":"","url":"https://clinicaltrials.gov/study/NCT05652894","created_at":"2022-12-15T14:58:22.933Z","updated_at":"2024-07-02T16:35:59.061Z","phase":"Phase 3","brief_title":"A Study of HX008 Compared to Chemotherapy in the First-Line Treatment of Subjects With MSI-H/dMMR Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05652894","lead_sponsor":"Taizhou Hanzhong biomedical co. LTD","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan • Puyouheng (pucotenlimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 190","initiation":"Initiation: 12/20/2022","start_date":" 12/20/2022","primary_txt":" Primary completion: 01/19/2026","primary_completion_date":" 01/19/2026","study_txt":" Completion: 10/20/2028","study_completion_date":" 10/20/2028","last_update_posted":"2022-12-15"},{"id":"dfc0498f-b919-4bcd-bed4-382201d39665","acronym":"","url":"https://clinicaltrials.gov/study/NCT05647954","created_at":"2022-12-13T14:57:57.763Z","updated_at":"2024-07-02T16:35:59.181Z","phase":"Phase 3","brief_title":"A Study of HX008 Plus Transcatheter Arterial Chemoembolization (TACE) in the First-Line Treatment of Subjects With Stage IV (M1c) Melanoma That is Metastatic to the Liver","source_id_and_acronym":"NCT05647954","lead_sponsor":"Taizhou Hanzhong biomedical co. LTD","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • temozolomide • Puyouheng (pucotenlimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 350","initiation":"Initiation: 12/31/2022","start_date":" 12/31/2022","primary_txt":" Primary completion: 12/30/2024","primary_completion_date":" 12/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2022-12-13"},{"id":"1b9cb10e-2252-4335-9ece-a59479724513","acronym":"","url":"https://clinicaltrials.gov/study/NCT05338957","created_at":"2022-04-21T14:55:36.910Z","updated_at":"2024-07-02T16:35:59.801Z","phase":"Phase 1/2","brief_title":"A Study of MRG002 in the Treatment of Patients With HER2-expressed Advanced Malignant Solid Tumors.","source_id_and_acronym":"NCT05338957","lead_sponsor":"Shanghai Miracogen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab) • trastuzumab vedotin (MRG002)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/05/2022","start_date":" 08/05/2022","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 12/01/2024","study_completion_date":" 12/01/2024","last_update_posted":"2022-12-01"},{"id":"88667f1b-98a0-4422-b87f-eee21f1cbfb9","acronym":"CHANGEABLE","url":"https://clinicaltrials.gov/study/NCT04508803","created_at":"2021-01-18T21:36:41.487Z","updated_at":"2024-07-02T16:36:08.019Z","phase":"Phase 2","brief_title":"Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer","source_id_and_acronym":"NCT04508803 - CHANGEABLE","lead_sponsor":"Fudan University","biomarkers":" HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC","pipe":" | ","alterations":" HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression","tags":["HER-2 • BRCA1 • BRCA2 • PTEN • BAP1 • CDK12 • CHEK2 • FANCA • BRIP1 • RAD51C • RAD50 • RAD51D • CHEK1 • BARD1 • NBN • FANCF • WRN • FANCM • FANCD2 • FANCE • FANCC"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • BRCA2 mutation • BRCA1 mutation • HR positive • HER-2 negative • ATM mutation • PALB2 mutation • CDK12 mutation • BAP1 mutation • CHEK2 mutation • BRIP1 mutation • RAD51C mutation • FANCA mutation • HR positive + HER-2 negative • RAD50 mutation • BARD1 mutation • BLM mutation • CHEK1 mutation • FANCF mutation • MRE11A mutation • NBN mutation • FANCM mutation • CHEK1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • cisplatin • Zejula (niraparib) • Puyouheng (pucotenlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 09/14/2020","start_date":" 09/14/2020","primary_txt":" Primary completion: 11/20/2022","primary_completion_date":" 11/20/2022","study_txt":" Completion: 12/28/2022","study_completion_date":" 12/28/2022","last_update_posted":"2022-06-30"},{"id":"8986dd83-96c8-4329-b6a5-a8ca32ccd281","acronym":"","url":"https://clinicaltrials.gov/study/NCT03704246","created_at":"2021-01-18T18:09:05.814Z","updated_at":"2024-07-02T16:36:33.788Z","phase":"Phase 2","brief_title":"Recombinant Human Anti-PD-1 Monoclonal Antibody HX008 Injection for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT03704246","lead_sponsor":"Taizhou Hanzhong biomedical co. LTD","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 123","initiation":"Initiation: 09/30/2018","start_date":" 09/30/2018","primary_txt":" Primary completion: 12/30/2019","primary_completion_date":" 12/30/2019","study_txt":" Completion: 03/30/2021","study_completion_date":" 03/30/2021","last_update_posted":"2021-03-04"},{"id":"16a08196-e3fa-48dc-968e-2853322717f1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04756934","created_at":"2021-02-16T12:53:57.352Z","updated_at":"2024-07-02T16:36:34.534Z","phase":"Phase 1","brief_title":"A Study of HX008 Plus LP002 for the Treatment of Patients With Advanced Melanoma","source_id_and_acronym":"NCT04756934","lead_sponsor":"Taizhou HoudeAoke Biomedical Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab) • LP002"],"overall_status":"Recruiting","enrollment":" Enrollment 63","initiation":"Initiation: 08/20/2020","start_date":" 08/20/2020","primary_txt":" Primary completion: 08/20/2021","primary_completion_date":" 08/20/2021","study_txt":" Completion: 08/20/2022","study_completion_date":" 08/20/2022","last_update_posted":"2021-02-16"},{"id":"79c7a8c6-853d-482a-969a-08ce04ef90c7","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750083","created_at":"2021-02-11T12:52:47.748Z","updated_at":"2024-07-02T16:36:34.731Z","phase":"Phase 2/3","brief_title":"HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04750083","lead_sponsor":"Taizhou Hanzhong biomedical co. LTD","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • carboplatin • pemetrexed • Puyouheng (pucotenlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 700","initiation":"Initiation: 09/25/2020","start_date":" 09/25/2020","primary_txt":" Primary completion: 09/25/2022","primary_completion_date":" 09/25/2022","study_txt":" Completion: 09/25/2023","study_completion_date":" 09/25/2023","last_update_posted":"2021-02-11"},{"id":"7b45916e-7e02-4429-baa3-9626d2c544d1","acronym":"HX008-II-MM-01","url":"https://clinicaltrials.gov/study/NCT04749485","created_at":"2021-02-11T12:52:41.595Z","updated_at":"2024-07-02T16:36:34.790Z","phase":"Phase 2","brief_title":"A Study of HX008 for the Treatment of Patients With Malignant Melanoma","source_id_and_acronym":"NCT04749485 - HX008-II-MM-01","lead_sponsor":"Taizhou Hanzhong biomedical co. LTD","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 119","initiation":"Initiation: 11/08/2018","start_date":" 11/08/2018","primary_txt":" Primary completion: 08/19/2020","primary_completion_date":" 08/19/2020","study_txt":" Completion: 11/08/2021","study_completion_date":" 11/08/2021","last_update_posted":"2021-02-11"},{"id":"d70ffd90-24bd-42f7-b579-0b436e6f98d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750382","created_at":"2021-02-11T12:52:51.079Z","updated_at":"2024-07-02T16:36:34.747Z","phase":"Phase 1/2","brief_title":"A Study of HX008 for the Treatment of Patients With Metastatic Triple Negative Breast Cancer","source_id_and_acronym":"NCT04750382","lead_sponsor":"Taizhou Hanzhong biomedical co. LTD","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 negative • PGR negative","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative • PGR negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • gemcitabine • Puyouheng (pucotenlimab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 31","initiation":"Initiation: 07/15/2019","start_date":" 07/15/2019","primary_txt":" Primary completion: 12/01/2020","primary_completion_date":" 12/01/2020","study_txt":" Completion: 12/01/2021","study_completion_date":" 12/01/2021","last_update_posted":"2021-02-11"},{"id":"eb09fcca-829e-444b-8576-e5a26a221e82","acronym":"","url":"https://clinicaltrials.gov/study/NCT04486651","created_at":"2021-01-18T21:32:18.296Z","updated_at":"2024-07-02T16:36:35.394Z","phase":"Phase 3","brief_title":"HX008 Plus Irinotecan Versus Placebo Plus Irinotecan as Second-line Treatment in Advanced Gastric Cancer","source_id_and_acronym":"NCT04486651","lead_sponsor":"Taizhou Hanzhong biomedical co. LTD","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • Puyouheng (pucotenlimab)"],"overall_status":"Recruiting","enrollment":" Enrollment 560","initiation":"Initiation: 09/16/2020","start_date":" 09/16/2020","primary_txt":" Primary completion: 08/10/2023","primary_completion_date":" 08/10/2023","study_txt":" Completion: 08/10/2023","study_completion_date":" 08/10/2023","last_update_posted":"2021-01-28"},{"id":"91d09991-0ff4-45a4-91a3-8c453d5c199d","acronym":"","url":"https://clinicaltrials.gov/study/NCT04574817","created_at":"2021-01-18T21:50:30.903Z","updated_at":"2024-07-02T16:36:40.443Z","phase":"Phase 2","brief_title":"Study of HX008 for the Treatment of Anaplastic Thyroid Cancer (ATC)","source_id_and_acronym":"NCT04574817","lead_sponsor":"Taizhou Hanzhong biomedical co. LTD","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Puyouheng (pucotenlimab)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 05/30/2022","primary_completion_date":" 05/30/2022","study_txt":" Completion: 05/30/2023","study_completion_date":" 05/30/2023","last_update_posted":"2020-10-05"}]